Explore RealPatient

Take a closer look at real-world evidence and clinical studies for CAR-T therapy in patients with diffuse large-B cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL). Select your patient type to get started!

Select an indication:

DLBCL ALL

Tisagenlecleucel is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of:
- Pediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.
- Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
- Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

09/23 159972-1